Vasaprostane lyophilisate solution for infusion 20 µg 48.2mg amp, 10pcs

Composition

1 ampoule contains alprostadil (in the form of alpha-cyclodextrin) 20 mcg;

excipients:

lactose;

alfadex.

Pharmacological action

Vasodilator, antiplatelet.

Vazaprostan-prostaglandin E 1 preparation. Improves microcirculation and peripheral blood circulation.

Reduces the tone of arterioles and postcapillary sphincters, reduces OPSS without changing blood pressure, increases coronary blood flow and left ventricular ejection fraction.

Improves the rheological properties of blood by reducing platelet adhesion and aggregation, reducing aggregation and improving the deformability of red blood cells, increasing fibrinolytic activity and reducing blood viscosity.

It has an effect on metabolism, increases the utilization of glucose and oxygen, inhibits the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates protein synthesis, has a beneficial effect on lipid metabolism (suppression of cholesterol synthesis and reduction of LDL concentration), inhibits proliferation and mitosis of smooth muscle cells.

Against the background of treatment with Vasaprostan, the severity of pain at rest decreases, the healing of trophic ulcers accelerates, and remission occurs during the course of the disease.

Indications

Treatment of chronic obliterating arterial diseases of stages III and IV.

Contraindications

chronic heart failure in the stage of decompensation; – acute myocardial infarction and post-infarction period within 6 months; – severe heart rhythm disturbances; acute circulatory failure (shock, vascular collapse); – severe hypotension (systolic BP less than 90 mm Hg. St. ) – pronounced violations of the liver; – stomach ulcer and duodenal ulcer; – hypersensitivity to the drug.

Side effects

From the cardiovascular system:  palpitations, hypotension, headache; in isolated cases-increased frequency of angina attacks, the development of pulmonary edema, the phenomena of heart failure.

From the digestive system:  dyspeptic phenomena, increased activity of hepatic transaminases.

Other services:  leukopenia, leukocytosis; with prolonged therapy (more than 4 weeks) in isolated cases, hyperostosis of the tubular bones.

Local reactions:  swelling, hyperemia, pain at the injection site.

Interaction

When used concomitantly, Vazaprostan may enhance the antihypertensive effect of antihypertensive drugs, peripheral vasodilators, and antianginal medications.

When Vazaprostan is used in combination with anticoagulants, antiplatelet agents, the likelihood of developing hemorrhagic syndrome increases.

How to take, course of use and dosage

Vazaprostan can be administered intravenously and intravenously.

To obtain a solution for intra-arterial use,20 micrograms (the contents of one ampoule) should be dissolved in 50 ml of saline solution. When conducting an intravenous infusion,25 ml of the resulting solution (10 micrograms of alprostadil) should be administered within 60-120 minutes using a special device for intravenous infusion. If necessary (especially for necrosis), the dose can be increased to 50 ml (20 mcg). If the drug is administered through an established catheter, an intravenous infusion is performed for 12 hours at a dose of 0.1-0.6 ng / kg of body weight per minute (corresponding to 12.5-25 ml of Vasaprostan solution).

For preparation of solution for intravenous injection 40 mg (the contents of the two vials) of dry matter to be dissolved in 50-250 ml of saline and enter the resulting solution/drip for 2 hours,2 times/day, or dissolve 60 g (content 3 vials) in 50-250 ml of saline and administered in/in drip for 3 hours,1 time/day.

In patients with impaired renal function (creatinine concentration greater than 1.5 mg/dl), intravenous use of Vasaprostan should begin with 10 mg 2 times a day, the duration of each infusion is 2 hours. If well tolerated for 2-3 days, the dose can be increased to the usual one. The duration of one course of treatment should not exceed 4 weeks.

Overdose

Symptoms:  decreased blood pressure, hyperemia of the skin, weakness.

Treatment:  the infusion of the drug should be slowed down or stopped; if necessary, symptomatic therapy is performed.

Special instructions

During treatment with Vasaprostan, patients with signs of renal and heart failure should limit the volume of fluid to 50-100 ml / day.

During therapy, blood pressure and heart rate should be monitored, and if necessary, fluid balance monitoring, central venous pressure measurement, and echocardiography should be performed. The clinical effectiveness of treatment is evaluated after 3 weeks of therapy.

Against the background of Vasaprostan therapy, the appearance of C-reactive protein may occur during a biochemical blood test.

Form of production

Lyophilizate for the preparation of an infusion solution.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Alprostadil

Conditions of release from pharmacies

By prescription

Dosage form

solution for infusions

Description

For adults as directed by your doctor

Indications

Microcirculation disorders